Funding for this research was provided by:
U.S. Department of Defense (W81XWH-16-1-0076, W81XWH-16-1-0761)
National Eye Institute (EY023427)
Text and Data Mining valid from 2019-11-05
Received: 4 June 2019
Revised: 21 September 2019
Accepted: 30 September 2019
First Online: 5 November 2019
Ethics approval and consent to participate
: Studies involving human adipose tissue were approved by the UTHSC Institutional Review Board in accordance with relevant guidelines and regulations following the tenets of the Declaration of Helsinki. Institutional IRB approved the study as exempt since the study involved de-identified cell lines from commercial sources, and therefore, consent to participate does not apply. All animal studies were conducted according to our previously published protocol [CitationRef removed] and were approved by the Institutional Animal Care and Use Committee, UTHSC, Memphis (IACUC ID: 16-110) and USAMRMC Animal Care and Use Review Office (Protocol No. VR150072) following the guidelines DOD Instruction 3216.01, “Use of Animals in DOD Programs.”
: Not applicable.
: NS and RG are co-founders and hold equity in Cell Care Therapeutics, Inc., whose interest is in the use of adipose-derived stromal cells in visual disorders. MP and LK are employees of Cell Care Therapeutics, Inc. with equity. All other authors declare that they have no competing interests.